Given these inconsistent findings in preclinical models and the well-established cardiovascular risks observed in oncology patients, systemic bevacizumab is unlikely to be a suitable candidate for repurposing in the treatment of atherosclerosis, though local or genetic delivery of VEGFA-blocking agents may still warrant exploration [46]. Here, VEGFA is linked to atherosclerosis.